Archive | Clinical Trials

Idera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Treatment

ORLANDO, Fla., Feb. 24, 2017 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today is reporting additional data from the dose-escalation phase of its ongoing Phase 1/2 clinical trial of intratumoral IMO-2125, an agonist of TLR9 in combination with […]

Read the full story

Posted in Melanoma In The News, Clinical Trials

Combos Mark Next Step in Melanoma Immunotherapy

Evidence continues to build for the long-term efficacy of PD-1–targeting immunotherapies in melanoma, including fresh data indicating when patients can stop taking the drugs and still maintain a response, according to Tara C.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Number of Baseline Melanoma Sites Predictive of OS in Dabrafenib/Trametinib Study

Dabrafenib (Tafinlar) combined with trametinib (Mekinist) continued to demonstrate durable efficacy for patients with BRAF V600E/K-mutant melanoma across patient subgroups in a 3-year analysis of the phase III COMBI-d study, with the amount of baseline sites of metastasis identified as a predictor of overall survival (OS) ?36 months, according to findings presented at the 2016 […]

Read the full story

Posted in Melanoma In The News, Clinical Trials

Acquired and Lost BRAF/MEK Resistance in Melanoma: A Prospective Study

Rechallenge with dabrafenib and trametinib among patients who progressed with BRAF inhibition with or without MEK inhibition may be effective in patients with BRAFV600-mutant melanoma, according to a study published in The Lancet Oncology.

Read the full story

Posted in Melanoma In The News, Clinical Trials, Other Melanoma Research

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories